Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 66Myelodysplastic Syndromes 38Leukemia, Myelomonocytic, Chronic 26Leukemia 14Myeloproliferative Disorders 10Recurrence 7Lymphoma 7Hematologic Neoplasms 7Neoplasms 6Primary Myelofibrosis 5Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm, Residual 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Glioblastoma 2Carcinoma, Renal Cell 2Anemia, Refractory, with Excess of Blasts 2

Interventions

Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Myeloid Malignancy × Azacitidine × Clear all
NCT07011186 2025-06-08

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
138 enrolled

Myeloid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡